

Dusting Off the Delicacy of Platelets

Platelets (PLTs) have the shortest shelf life of any blood components, lasting for only five days. They are also in demand. While red blood cell demand has fallen by more than 20 percent in recent years, there has been a slight uptick in recent years for PLTs. One method being investigated to support a longer lasting PLT product is freeze-drying and only one company seems to be actively performing research trials with this technique.

Rockville, Md.-based PLT lab Cellphire, Inc., has completed their first human exploratory Investigational New Drug (IND) trial, the results of which are under internal review. President and Director of Research and Development at Cellphire, G. Michael Fitzpatrick, PhD (former ABC COO), said they and participating blood center Bloodworks Northwest intend to publish the results by mid-2017. After extensive animal studies, no safety issues were seen on infusion of their product in 15 healthy adults.

"It's important for people to know there are alternate forms of platelets other than room temperature platelets in the pipeline being evaluated as a hemostatic agent in surgical settings," said Sherrill J. Slichter, MD, director of Platelet Transfusion Research at Bloodworks Northwest, and professor of medicine at the University of Washington School of Medicine.

Cellphire uses a proprietary method of freeze-drying PLTs by adding the sugar trehalose, and other small compounds into the cellular compartments of the PLTs. The proprietary lyophilization process freezes the solution, then heats the frozen product under vacuum, allowing the water to come off as a gas. The trehalose essentially replaces the water and stabilizes the

membrane, keeping it intact. The dried product is stored in 10 cubic centimeter vials, and then be rehydrated with sterile water. Once rehydrated it is infused intravenously within one hour. The name of the product is Thrombosomes®.



Dr. Fitzpatrick with a vial of Thrombosomes

"It's been known that there are some plants and even bugs who survive in desiccation. Trehalose is produced naturally by plants and micro-animals (Tardigrades, "water bears") to replace water in their cells and enable that survival. They produce trehalose internally to and have a very slow metabolisms. A plant called the resurrection plant or Rose of Jericho (*selaginella lepidophylla*) dries up and looks dead, but once it is exposed to water, it comes back to life," explained Dr. Fitzpatrick on the origin of the idea.

A number of studies over the last 12 years have demonstrated that freeze-dried PLTs retain growth proteins and wound healing properties (Ho D., *et al*; Sum R., *et al*; Pietramaggiore, *et al*). But no one else is performing this type of research on humans with this method on this scale, said Dr. Fitzpatrick. A similar company

Issue #2
January 20, 2017

INSIDE:

Our Space:

A Call to Service 2

Congratulations to the
ABC Annual Meeting
Scholarship Awardees . 3

Nominate ABC Committee
Members 3

RESEARCH IN BRIEF 5

WORD IN WASHINGTON
..... 6

BRIEFLY NOTED 6

REGULATORY NEWS ... 6

INFECTIOUS DISEASE
UPDATES 6

PEOPLE 7

STOPLIGHT®: Status of
the ABC Blood Supply . 8

New ADRP Listserv Helps
Subscribers Stay
Connected 8

MEMBER NEWS 9

GLOBAL NEWS..... 9

COMPANY NEWS..... 9

CALENDAR 10

POSITIONS 11



OUR SPACE

Kate Fry, ABC's Chief Administrative Officer

A Call to Service

This week, [a call for committee volunteer members was issued](#) to ABC members for our fiscal years 2018 and 2019. ABC committee volunteers are the backbone of ABC and represent the best and brightest from throughout the industry. The altruistic spirit of these volunteers pushes the needle forward in work that spans all segments of the blood center. Simply put, we couldn't do it without you.

With current committees and subcommittees sun-setting at the end of ABC's fiscal year 2017 this March, now is the time to express your interest in serving on one of our many committees. Service on committees provides a multitude of unique opportunities for the individual, the blood centers, and our association: including, participating in ABC's decision-making and policy-forming processes, identifying emerging issues, providing feedback and guidance, planning meetings, workshops and forums, and, of course, furthering your own professional development.

New this year is the America's Blood Centers Professional Institute (API) Leadership & Meetings Committee that will focus solely on planning the annual and summer meeting Blood Center Leadership Forums. This committee will also recommend topics and speakers for specialty workshops, webinars, and other means of member education. In addition, the following committees are currently accepting nominations: API Member Employee Training & Development, Audit, Communications & Donor Management, Finance, Government Affairs Committee, Human Resources, Information Technology, Membership, Quality and its subcommittees, Scientific, Medical and Technical (SMT) and its subcommittees, and the Technical/Lab Directors committee.

The nomination form, and a full list of committee charters and charges can be found [here](#). Nominations are due by Tuesday, February 7. We hope you will help ABC, and your blood center, achieve excellence and apply today.

KFry@americasblood.org

The *ABC Newsletter* (ISSN #1092-0412) is published 46 times a year by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2017 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC is an association of not-for-profit, independent community blood centers that helps its members provide excellence in transfusion medicine and related health services. ABC provides leadership in donor advocacy, education, national policy, quality, and safety; and in finding efficiencies for the benefit of donors, patients, and healthcare facilities by encouraging collaboration among blood organizations and by acting as a forum for sharing information and best practices.

America's Blood Centers

President: Susan Rossmann

CEO: Christine S. Zambricki

Editor: Lisa Spinelli

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

lmaundy@americasblood.org

America's Blood Centers

725 15th St. NW, Suite 700, Washington, DC 20005

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

Congratulations to the ABC Annual Meeting Scholarship Awardees

ABC is excited to announce the ABC Annual Meeting Scholarship Awardees. The scholarship is made possible every year by a grant from the Foundation for America's Blood Centers (FABC), which helps to supplement the costs for attendance to an ABC specialty workshop or meeting.

We are pleased to announce scholarships were awarded to the following ABC members: Mia Cochran, donation suitability coordinator at Blood Bank of Delmarva; Maria De Los Angeles Muñiz, MD, medical director at Community Blood Services in N.J.; and Larry Shaw, senior program manager at Bloodworks Northwest. Congratulations to all recipients!

Nominate ABC Committee Members

Our association is made stronger by the sharing of knowledge from our members. The volunteers that make up our committees help foster this exchange of ideas and sharing their wealth of knowledge. On March 31, 2017, all current committee memberships will expire. We are now looking for nominations to our volunteer committees that will last for the next two years.

We strongly encourage all Member Voting Representatives and their staff to review the listing of committees and their charters/charges (this information is located within our [survey](#)) to determine interest in serving on a particular committee.

Here are some resources that may help in your decision making process: [Our Confidentiality & Conflict of Interest Policy](#); the [ABC Committee Overview FY 18-19](#).

Thank you for your time, consideration, and commitment to helping ABC. Please feel free to contact [Mack Benton](#) with any additional questions. ♦

ABC Webinar

"9 Ways to Energize, Empower and Engage Your Employees"

February 7, 2017

2 p.m. EST

Join us for this webinar on how to energize, empower, and engage employees and their individual strengths to maximize both the individual's and an organization's success. The webinar is February 7, 2017, at 2 p.m. EST and will be presented by Gary Markle, executive coach and founder of consulting firm Energage. Register for the webinar [here](#).



DUSTING OFF THE DELICACY OF PLTS (continued from page 1)

named Entegron, in North Carolina, was testing a freeze-dried PLT product called Stasix® at least two years ago; however, they do not have any Food and Drug Administration (FDA)-filed clinical trials open.

“Our development is on hold right now, but we have performed some preclinical trials on animals. Some interesting research demonstrated the platelet derived growth factors survived the freeze-drying process,” said Mike Galiger, vice president of operations at Entegron. “We’re pretty excited about Stasix, because there are a lot of autologous replacement-therapy products out there, but we believe we might have a product for allogenic usage as well.”

Cellphire increased their workforce from four full-time staff members to 28 after a \$57 million grant from the Biomedical Advanced Research and Development Authority (BARDA) was finalized in 2013. The grant aided in the manufacturing, development, performing clinical studies through a phase two human trial, and investigating the use of Thrombosomes® to support radiation casualties during treatment.

Their IND study on Thrombosomes® lasted two and a half years, ending in late 2016 with 15 patients, all of whom received one infusion made from autologous PLTs at anywhere from 1/1000 to 1/10 of the estimated clinical dose. ABC member blood center Bloodworks Northwest collected the apheresis PLTs used. They were processed at Cellphire, and tested for stabilization before the products were shipped back to Bloodworks Northwest for infusion. The participants were then evaluated at regular intervals during the first 24 hours, at three, seven days, 42 and, in one study group, 60 days after infusion.

Cellphire is planning a phase one clinical trial with 12 patients at higher doses. The submission for the trial is under review by the FDA. Safety recovery and survival studies will be running concurrently to assess how long the PLTs stay in circulation. Dr. Fitzpatrick said the half-life of the Thrombosomes® PLTs is believed to be much shorter than unmodified PLTs. Animal data have demonstrated hemostatic effect.

“A smaller dose is more effective than a room-temperature liquid platelet unit. One Thrombosomes® unit may provide four or five doses,” said Dr. Fitzpatrick. “For isolated hospitals in places like North Dakota or Alaska, they might have a hard time keeping platelets on-hand, this could expand their inventory. It could also help provide a hemostatic product for use by first responders.”

The ultimate goal is to have a product that would complement liquid PLT units so a hospital could have an inventory of Thrombosomes® for treating acute bleeding in all patients, especially in the emergency or operating rooms and keep the room-temperature platelet inventory for prophylactic treatment for medicine and oncology patients who need a minimum level of circulating platelets,” said Dr. Fitzpatrick.

They are also developing an animal product for dogs. Trials for that product are scheduled to begin this year. The company has a dedicated animal PLT lab for research as well as to manufacture a canine PLT product called Stable Plate, which could be available for clinical use in dogs as early as late summer 2017.

Citations: Ho D., Moskowitz K., Sum R., *et al.* Wound Healing Properties of Reconstituted Freeze-Dried Platelets. *Wound Repair and Regeneration*. March 2005. DOI: 10.1111/j.1067-1927.2005.130215bt.x

Pietramaggiore G., Kaipainen A., Czeczuga J.M., *et al.* Freeze-dried platelet-rich plasma shows beneficial healing properties in chronic wounds. *Wound Repair and Regeneration*. September 29, 2006. DOI: 10.1111/j.1743-6109.2006.00164.x.

Sum R., Hager S., Pietramaggiore G., *et al.* Wound-healing properties of trehalose-stabilized freeze-dried outdated platelets. *Transfusion*. April 2007. DOI: 10.1111/j.1537-2995.2007.01170.x.

Fitzpatrick G.M., Cliff R., and Tandon N. Thrombosomes: a platelet-derived hemostatic agent for control of noncompressible hemorrhage. *Transfusion*. January 2013. DOI: 10.1111/trf.12043. ♦



RESEARCH IN BRIEF

Assay detects variant Creutzfeldt-Jakob disease (vCJD) during and before clinical onset. A French trial that combines plasminogen-bead capture and protein misfolding cyclic amplification (PMCA) detected vCJD pathogenic prions at 100 percent sensitivity. There is no effective test to detect pre-symptomatic vCJD patients and existing noninvasive diagnostic methods for symptomatic patients have only demonstrated around 70 percent sensitivity in blinded studies. In this study of 256 plasma samples, including 18 patients with clinical vCJD and 67 with sporadic Creutzfeldt-Jakob disease from France and the United Kingdom, the assay identified symptomatic and asymptomatic cases with 100 percent sensitivity. The assay also allowed the detection of two silent carriers of prions before the clinical onset of vCJD developed. However, the samples had to be tested with three rounds of PMCA of 80 cycles each for complete detection, each cycle requiring approximately 30 minutes. Prion detection after amplification used Western Blot.

Citation: Bougard D., Brandel J.P., B elondrade M., *et al.* Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. *Science Translational Medicine*. December 21, 2016. DOI: 10.1126/scitranslmed.aag1257.

Another study of variant Creutzfeldt-Jakob disease (vCJD) detection using protein misfolding cyclic amplification (PMCA) in blood samples provided 100 percent sensitivity. This U.S.-based study was performed on samples from 14 cases of vCJD and 153 controls, including patients with sporadic Creutzfeldt-Jakob disease and other neurological disorders as well as healthy people. Blood analysis was performed on as little as a few microliters of blood with 100 percent sensitivity.

Citation: Concha-Marambio L., Pritzkow S., Moda F., *et al.* Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. *Science Translational Medicine*. December 21, 2016. DOI: 10.1126/scitranslmed.aaf6188.

A study of tranexamic acid before cardiac surgery showed a reduced risk of bleeding and mortality. Researchers enrolled 4662 patients in a randomized, blinded study of the inhibitor of fibrinolysis, tranexamic acid, and compared receipt of blood transfusions (red cells, platelets, or fresh frozen plasma) during their hospital stays. There were significantly lower rates of transfusion, reoperation blood loss, and death in the tranexamic acid group. However, the tranexamic acid group did show a significant increase in seizures. There was no impact on hospital length of stay.

Citation: Myles P.S., Smith J.A., Forbes A., *et al.* Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. *The New England Journal of Medicine*. January 12, 2017. DOI: 10.1056/NEJMoa1606424.

Myasthenia gravis (MG) patients had a significant response to rituximab (anti-CD20 directed against B-cells) in a new study. Patients with this chronic autoimmune disease generally take immunosuppressive drugs that can have potentially serious side effects. In an eight-year study, researchers gave 16 acetylcholine receptor autoantibody-positive (AChR+) generalized MG patients rituximab and followed them for up to 84 months. All of the patients were able to reduce or completely withdraw their use of other immunotherapies, 63 percent had complete remission after one cycle, and a significant number of them (44 percent) remained relapse-free after a mean 47 months. An accompanying opinion piece noted rituximab has been studied with promising results over the last 17 years, however, the treatments are extremely costly—\$30,000 per treatment cycle. The comment suggests that for AChR and muscle specific kinase antibody positive refractory MG, the cost-benefit ratio is favorable despite the high upfront expense.

(continued on page 6)



RESEARCH IN BRIEF (continued from page 5)

Citations: Robeson K.R.; Kumar A., Keung B., *et al.* Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis. *JAMA Neurology*. November 21, 2016 online. DOI: 10.1001/jamaneurol.2016.4190.

Silvestri N.J. and Wolfe G.I. Rituximab in Treatment-Refractory Myasthenia Gravis. *JAMA Neurology*. January 2017. DOI: 10.1001/jamaneurol.2016.4367. ♦

BRIEFLY NOTED

More ways to sterilize the *Aedes aegypti* mosquito. Michigan State University's Zhiyong Xi, PhD, director of the Sun Yat-sen University Michigan State University Joint Center of Vector Control for Tropical Diseases, was awarded \$1 million grant to build a mosquito factory in Yucatan, Mexico. The *Aedes aegypti* mosquitoes—responsible for the spread of Zika, yellow fever, dengue and chikungunya—will be infected with the Wolbachia bacteria, which is safe for humans, at the facility. The mosquitoes then mate and the bacteria causes the females to become sterile. The concept was taken from a facility in Guangzhou, China, which Xi heads as well. (Source: [MSU press release](#), January 4, 2017) ♦

REGULATORY NEWS



Two names have been thrown into the hat to be considered as head of the Food and Drug Administration (FDA). Jim O'Neill, managing director of global investment firm Mithril Capital Managements, was named last month as a candidate. Balaji Srinivasan, an investor and entrepreneur in Silicon Valley, reportedly met with President-elect Trump to discuss leading the agency this past week. Both have been critics of the long lag time it takes the FDA to go from drug concept to approval. The other leading FDA candidate is Scott Gottlieb, MD, who has strong bi-partisan support and whom we reported on in [Newsletter #45](#) in 2016. (Source: STAT News, [Two Silicon Valley insiders meet with Trump about heading FDA](#), January 12, 2017) ♦

INFECTIOUS DISEASE UPDATES

Genetically altered malaria parasite produces promising trial results. *Falciparum* malaria is responsible for tens of thousands of deaths annually, and for a substantial proportion of the transfusion requirements in sub-Saharan Africa, making a vaccine a high priority. Investigators in Seattle published a study of 10 volunteers experimentally infected with a genetically engineered malaria parasite (*Plasmodium falciparum*) with three genes, essential for the parasite's pre-erythrocytic development in the liver, deactivated. The

WORD IN WASHINGTON



The Senate Committee on Health, Education, Labor, and Pensions (HELP) held the first nomination hearing for Tom Price, MD, on January 18. Representative Tom Price (R-Ga.) has been nominated to be the Secretary of the Department of Health and Human Services. Rep. Price fielded questions from Democrats on what some have called inappropriate financial investments and holdings, including tobacco company stock and purchasing stock in a medical device company after legislation passed that would benefit the company. Claiming no wrong doing, Rep. Price also took questions regarding his stance on the Affordable Care Act, and stated a number of times that he believes all people deserve to have health care coverage they can afford. He said he does not believe the ACA is providing that kind of fair coverage. He will next face the Senate Finance Committee on January 24. (Source: [HELP website](#), January 18, 2017) ♦




INFECTIOUS DISEASE UPDATES (continued from page 6)

candidate vaccine produced a robust humoral immune response, and provided complete protection from clinical malaria.

Citation: Kublin J.G., Mikolajczak S.A., Sack B.K. *et al.* Complete attenuation of genetically engineered *Plasmodium falciparum* sporozoites in human subjects. *Science Translational Medicine*. January 4, 2017. DOI: 10.1126/scitranslmed.aad9099.

Transfusion hepatitis E virus (HEV) in French transplant recipients. In a retrospective study of 60 solid organ transplant recipients over a five year period (January 2009 to June 2014), researchers found the rate of transfusion-transmitted HEV to be 11.7 percent, or seven of the patients. While these seven potentially contracted HEV through a transfusion, the remaining 53 HEV-positive patients were infected by other means.

Citation: Lhomme S., Bardiaux L., Abravanel F., *et al.* Hepatitis E virus infection in solid organ transplant recipients, France. *Emerging Infectious Diseases*. February 2017. DOI: 10.3201/eid2302.161094. ♦



PEOPLE




Marsha Bertholf, MD, has been appointed to the position of medical director for Gulf Coast Regional Blood Center (GCRBC). She will begin her new position in early February 2017. “Dr. Bertholf will bring a tremendous amount of knowledge and experience to Gulf Coast Regional Blood Center,” said Chief Medical Officer at GCRBC and ABC President Susan N. Rossmann, MD, PhD. “Her expertise will provide invaluable support to our organization’s lifesaving mission, and we look forward to welcoming her on board.” Dr. Bertholf graduated from the University of North Carolina Greensboro, with a major in Biology and then became a certified medical technologist. She earned her MD from the University of North Carolina and was a resident in Anatomic and Clinical Pathology at the University of Virginia, where she also pursued a fellowship in Blood Banking and Transfusion Medicine. She is board certified in Anatomic and Clinical Pathology and Blood Banking and Transfusion Medicine. Most recently, she served as the medical director at OneBlood in Jacksonville, Fla., formerly The Blood Alliance, since 1994. ♦

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste. Please send letters to ABC Publications Editor Lisa Spinelli at newsletter@americasblood.org or fax them to (202) 393-1282. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.



STOPLIGHT®: Status of the ABC Blood Supply



Daily updates are available at:
www.AmericasBlood.org



New ADRP Listserv Helps Subscribers Stay Connected

The new ADRP Listserv provides idea sharing and networking from blood banking professionals across the globe. It provides both a recruitment and collections network of community forums. Subscribers may read other users' content and participate in discussions. Active ADRP subscribers are automatically registered for an account. Click [here](#) to subscribe. ♦



MEMBER NEWS



Central California Blood Center teamed up with area Rotary clubs and individuals to donate a bloodmobile to a blood center in the Ukraine. The bloodmobile, originally purchased in 1996 through funding from the Rotary District 5230, was loaded Friday, January 13, aboard a semi-truck for transport to Texas, and ultimately arrived in the city of Odessa, Ukraine. “The need for this vehicle in Ukraine is extraordinary and will make a difference for patients who depend upon blood for injuries and illnesses,” said Dean Eller, President and CEO of Central California Blood Center.

The bloodmobile was originally given in tribute to Mr. Eller’s daughter, Jennifer Eller, who lost her battle with leukemia. (Source: Central California Blood Center press release, January 13, 2016) ♦

GLOBAL NEWS



Ireland lifted the lifetime ban on men who have sex with men (MSM) from donating blood. The change happened Monday, January 16 and changed the lifetime ban to be a one-year deferral for MSM. Potential donors who have contracted a sexually transmitted disease are now being

told they will have to wait for five years after their treatment ends in order to donate blood as well. (Source: *Newsweek*, [Ireland Lifts Lifetime Ban on Gay Men Giving Blood](#). January 17, 2017) ♦

COMPANY NEWS

Valeant selling Provenge-maker Dendreon to Chinese conglomerate for \$820M. Valeant Pharmaceuticals International announced it has agreed to sell Dendreon Pharmaceuticals to Chinese group Sanpower. Dendreon is the developer of Provenge, an autologous cellular immunotherapy medication for advanced prostate cancers. Valeant experienced a hard financial year after catching negative media attention for increasing their prices for several of its drugs last year and after the Food and Drug Administration refused Salix Pharmaceuticals, a Valeant company, an application for a latanoprostene bunod ophthalmic solution, an eye drop for patients with glaucoma. (Sources: BioPharma Reporter, [Valeant selling Provenge maker Dendreon to Chinese conglomerate for \\$820M](#). January 10, 2017; Fierce Pharma, [Asia Report](#). January 13, 2017)



Haemonetics released a major upgrade to its donor management system (DMS). The NextGen DMS 4 “will enable automated donor address verification, paperless intake and annual medical assessment, and will extend capabilities of the donor floor mobile application to streamline

phlebotomy documentation,” reads the press release. The software update also houses new quality checklists with alerts to help centers follow their standard operating procedures. (Source: [Haemonetics press release](#), December 8, 2016). ♦



CALENDAR

2017

Feb. 8-9. **FDA Public Workshop: Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-Based Products, College Park, Md.** For more information, click [here](#).

Feb. 13-14. **AABB U.S. Hemovigilance Symposium, Atlanta, Ga.** [Click to register](#) and for more information.

February 13-15. **Pharma Conference: 13th Annual FDA and the Changing Paradigm for HCT/P Regulation, Alexandria, Va.** For more information, click [here](#).

Mar. 2-3. [IPFA 2nd Asia Workshop on Plasma Quality and Supply](#), Yogyakarta, Indonesia. To register for the workshop, click [here](#).

Mar. 24-28. **Annual Meeting, America's Blood Centers, Washington, D.C.** Contact: ABC Meetings Dept. Phone: (202) 654-2901; e-mail: meetings@americasblood.org.

Mar. 25. **Board Meeting, America's Blood Centers, Washington, D.C.** Contact: ABC Meetings Dept. Phone: (202) 654-2901; e-mail: meetings@americasblood.org.

April 6. **FDA Public Workshop: Emerging Tick-Borne Diseases and Blood Safety, Bethesda, Md.** For more information, click [here](#).

Apr. 18-19. **Heart of America Association of Blood Banks (HAABB) 50th Annual Spring Meeting, Kansas City, MO.** For more information and to register, go to <http://www.haabb.org>.

May 1-3. **ADRP 2017 Annual Conference, Chicago, Ill.** More information is available on the [website](#).

May 16-17. [IPFA/PEI 24th International Workshop on "Surveillance and Screening of Blood-borne Pathogens"](#), Zagreb, Croatia. To register, click [here](#).

May 17-19. **Cellular Therapies and Transfusion Medicine in Trauma and Critical Care-Looking Towards the Future, San Francisco, Calif.** Presented by Blood Systems, Blood Systems Research Institute, and the University of California San Francisco. For more information, or to register, click [here](#).

June 6-8. **Technical & Quality Workshops, America's Blood Centers, Omaha, Neb.** Contact: ABC Meetings Dept. Phone: (202) 654-2901; e-mail: meetings@americasblood.org.

June 17-21. **27th Regional Congress of the ISBT, Copenhagen, Denmark.** Click [here](#) to register for the event.

Aug. 1-4. **Summer Meeting, MD Workshop & Golf Tournament, America's Blood Centers, Providence, R.I.** Contact: ABC Meetings Dept. Phone: (202) 654-2901; e-mail: meetings@americasblood.org.

Aug. 4. **Board Meeting, America's Blood Centers, Providence, R.I.** Contact: ABC Meetings Dept. Phone: (202) 654-2901; e-mail: meetings@americasblood.org.

Sept. 11-12. [IPFA/BCA 3rd Global Symposium on The Future for Blood and Plasma Donations](#), Atlanta, Ga. [Registration will open in mid-September.](#) ♦



CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, contact Leslie Maundy at the ABC office. Phone: (202) 654-2917; fax: (202) 393-1282; e-mail: lmaundy@americasblood.org.

POSITIONS

Center Manager (Beaumont, Texas). LifeShare Blood Centers is currently seeking an individual to fill a key leadership position within our organization. The Center Manager is accountable for operational objectives and will ensure strategic plan is met. The position tracks and trends key performance indicators, quality metrics and financials and takes appropriate action to ensure the business viability. Bachelor's degree in Applied Sciences or Business required with MBA preferred. Demonstrated success of execution of strategic objectives in challenging and highly regulated environment. Ten years of progressive managerial experience required with experience managing donor recruitment and donor services a plus. LifeShare has been a part of the community since 1942, providing local hospitals and our employees with great benefits. To apply, please visit: www.lifeshare.org under the careers tab.

Medical Technologist (Shreveport, LA). LifeShare Blood Centers is currently looking for a Medical Technologist in our Reference Lab. The Med Tech performs complex antibody workups and compatibility testing of donor and patient blood samples, recording observed results, making interpretations, completing reports and paperwork required to charge accounts for testing. The Med Tech performs special serological tests to define immunohematological problems and coordinates investigations with LifeShare's molecular testing laboratory and communicates findings with requesting facility to assist with the determination of appropriate transfusion therapy. Bachelor's degree in Medical Technology or related science field required. MT(ASCP) or MLS(ASCP) or equivalent national accrediting organization required. Current CLS licensure or license eligible. Two to three year's blood banking experience. To apply, please visit: www.lifeshare.org under the careers tab.

President/CEO. Central California Blood Center is a successful growth oriented, independent, not-for profit organization serving hospitals in the Central San Joaquin Valley in California seeking a President/CEO. The successful candidate will have demonstrated leadership experience and must possess exceptional strategic planning abilities coupled with strong interpersonal skills to maintain and cultivate supportive relationships within the regional health care sector and the community and beyond. This executive leadership position is accountable for operational objectives providing leadership and direction to the organization in alignment with Board of Directors to ensure strategic plan is met to execute our

mission, vision and core values. Demonstrable success building teams to drive operational success in challenging and highly regulated environments required. Candidates Ten years progressive managerial experience and baccalaureate degree required with an MHA, MBA a plus. EOE/M/F/Vet/Disabled. Please submit resume with salary history via [email](mailto:), or regular mail to Dean Eller, Central California Blood Center, 4343 W. Herndon, Fresno, CA, 93722.

Scientist, Hematology. (Company: Cerus Corporation; Location: Concord, CA) Initiates, directs and executes scientific studies for multiple projects for the INTERCEPT Blood System. Focus on registration studies with external collaborators. Acts independently as Study Director: Experimental design, preparation of protocol, study execution, data analysis, and preparation of final report. Assists in planning and conduct of external registration studies. Notes trends and aberrations in data; identify problems and suggesting/conducting experiments to determine root cause and develop solutions. Participates on project teams providing contribution of ideas, developing of plans, execution of plans, and timely reporting of results. Ph.D. in a biology-related discipline preferred with a minimum of two years relevant experience or MS/MA in a biology-related discipline with a minimum of eight years relevant experience; BA/BS required with a minimum of 11 years relevant experience. Experience with platelet and RBC function and or plasma coagulation desirable. For full job description and to apply click [here](#).

Associate Director & Sr. Scientist, Platelet and Plasma Biology. (Company: Cerus Corporation; Location: Concord, CA) Lead research and/or development studies to support the INTERCEPT Platelet and Plasma platforms. Be a technical expert and key member of the Development team in the areas of plasma coagulation and/or platelet physiology. Direct studies to support both product development and commercial supply for the INTERCEPT System for platelets and plasma. Manage laboratory team to support product line extensions studies to meet corporate timelines. Interface with cross functional team leaders. Function as study director in designing, conducting and analyzing own experiments and, potentially, those performed at other sites. Ph.D., with a minimum of seven years relevant experience or master's degree in a scientific discipline with a minimum of 10 years' experience. For full job description and to apply click [here](#).

(continued on page 12)

POSITIONS (continued from page 11)**Reference Technologist III (Job 08030 Seattle (First Hill); Immunohematology Reference Laboratory).**

Bloodworks Northwest is currently seeking an experienced Medical Laboratory Technologist/Blood Bank Technologist to work in the Immunohematology Reference Laboratory (IRL) at our First Hill Seattle location. This position is eligible for sign on bonus and also offers great benefits and competitive pay. Requirements include: Bachelor of Science degree in clinical laboratory science or other biological science or equivalent; education must meet CMS/CLIA qualification requirements to perform high complexity testing. Also required are two years of immunohematology reference laboratory experience and current certification as MLS (ASCP), BB (ASCP) or MLT (ASCP) or equivalent certification. SBB(ASCP) certification is preferred. The requirement for two years of Immunohematology reference lab experience may be waived with SBB(ASCP) certification. Demonstrated familiarity with computers and keyboarding skills for performing order entry, and the ability to see red, green, blue and yellow are required. We are also looking for excellent customer service skills and the ability to prioritize and reprioritize, and handle tight deadlines, stressful situations and emergency requests. **IMPORTANT NOTICE REGARDING APPLYING:** Please visit our [website](#) and apply to either jobs 08029 or 08030. EEO Employer

Clinical Laboratory Scientist. Located in the heart of the magnificent coastal redwoods of Northern California, The Northern California Community Blood Bank is a nonprofit blood bank serving Humboldt and Del Norte Counties. The Northern California Community Blood Bank has an immediate opening for a Clinical Laboratory Scientist. The Clinical Laboratory Scientist is responsible for activities related to processing, testing, storage, transportation, and other handling of blood and blood products. The Clinical Laboratory Scientist performs reference immunohematological testing and participates in training, validation, implementation of new procedures, and compliance with regulatory and standard-setting agencies. Experience, Education and Licensure: Four-year degree from an accredited college or university in science, medical technology or a related field. Valid current California license as a Clinical Laboratory Scientist. Preferred experience as a technologist in a clinical laboratory and familiarity with standard laboratory methods and techniques, ability to perform standardized routine testing, specialized testing in blood donor processing, and immunohematology. Will train the right candidate. To apply, contact [Adam Summers](#), Northern California Community Blood Bank, 2524 Harrison Avenue, Eureka, CA 95501; (707) 443-8004.

Associate Medical Director. Michigan Blood seeks Physician, board certified in Clinical Pathology or Hematology and board certified in Transfusion Medicine (or eligible to achieve certification in the first year of employment), to assist in all medical/clinical aspects of

donor eligibility, therapeutic apheresis, transfusion medicine consultation and patient reporting from our clinical laboratories. Candidate will also assist with the medical and technical review of SOP's, validations and variances as assigned. Requirements include being a team player with excellent verbal and written communication skills. Experience in donor qualification, therapeutic apheresis and transfusion medicine consultation for transfusion service is preferred. Michigan Blood provides blood products and services for more than 70 hospitals throughout Michigan, and is an established leader in quality and service. In addition, Michigan Blood provides therapeutic apheresis, cellular therapies for the treatment of cancer and transfusion medicine consultations. We offer a competitive salary and benefit plan. If you like to work with people, have good communication and customer service skills, and the desire to make a lifesaving difference, please upload your resume and cover letter at: www.miblood.org.

Assistant Manager Donor Testing (Laboratory Supervisor). (Department: Donor Testing; Reports To: Manager Donor Testing Lab; Status: Full-time, 1.0FTE, and Exempt; Schedule: Monday – Friday, 3rd Shift 9 p.m. - 5:30 a.m.; Benefits: Medical, Dental, Vision, 401K, PTO / EST, to name a few!) Take the next step in your career in our high profile donor testing laboratory with our non-profit mission based organization. Primary Purpose: Manages testing laboratory 3rd shift staff and coordinates operations associated with testing blood donors for infectious disease and immune-hematology during these shifts. Provides adequate training and performance appraisals. To apply please go directly to our [website](#) with an updated resume.

Director of Collections (Minnesota Division). (Reports to: Vice President Donor Services; Status: Full-Time, 1.0FTE, and Exempt; Benefits: Medical, Dental, Vision, 401K, Life Insurance, PTO and EST and more) Directs all blood collections operations for the Minnesota donor centers and mobile operations. Provides guidance and oversight to the team that embodies the Innovative Blood Resources (IBR) mission and values and promotes successful collections processes/outcomes. Ensures collections operations and mobiles are run in a manner that results in safe and compliant blood products and services that consistently delights donors and sponsors. Ensures a working environment for the Minnesota Collections leaders and team that is supportive and productive through recognition, feedback, coaching and development. Responsible for collections team, collections support functions and vans/mobiles drivers. Provides guidance to collections leadership in budget development, staffing models, performance reviews, goal development and goal development and achievement. Works collaboratively with the Manager of Donor Recruitment, Manager of CMC, Manager of Collections Quality and Director of Donor Services in Nebraska. To apply please go directly to our [website](#) with an updated resume. 📌